CCN2 and idiopathic pulmonary fibrosis: For example, a monoclonal antibody against CTGF (also known as CCN2) is currently being evaluated in phase III clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) (62, 63), which showed also an improved cardiac repair through the downregulation of profibrotic and inflammatory genes in a mouse model of myocardial infarction (MI) (64).